Back to today’s briefing

Story perspectives

Hims & Hers Shares Plunge 20% Amid FDA Setback

2/23/2025

47 4

Summary

Hims & Hers Acquires Facility

Hims & Hers Health is grappling with a major setback as the FDA resolves the semaglutide shortage, leading to a 20% plunge in shares amid fears of dwindling sales. In response, the company is strategically acquiring a peptide facility to bolster its supply chain and diversify its product lineup, striving to navigate this shifting market.

Summary

FDA Lifts Semaglutide Shortage

The FDA has officially lifted the semaglutide shortage for Ozempic and Wegovy, enabling Novo Nordisk to satisfy U.S. demand. Compounding pharmacies can still create alternatives until April and May 2025. This change has shaken telehealth companies like Hims & Hers, leading to a notable decline in their market value as compounded options fade away.

History

Historical Context

The recent FDA resolution of the semaglutide shortage echoes historical drug supply crises, such as the 2012 meningitis outbreak that spurred regulatory reforms. These events highlight ongoing vulnerabilities in pharmaceutical supply chains, prompting companies like Hims & Hers to adapt by acquiring production capabilities to mitigate future disruptions.

1 of 3

Hims & Hers Acquires Facility

Hims & Hers Health is grappling with a major setback as the FDA resolves the semaglutide shortage, leading to a 20% plunge in shares amid fears of dwindling sales. In response, the company is strategically acquiring a peptide facility to bolster its supply chain and diversify its product lineup, striving to navigate this shifting market.

1 / 3